Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

otal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins Lymphoma (NHL). For additional information, please visit the Company's website at http://www.allos.com.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements relating to the potential safety and efficacy profile of PDX relative to methotrexate and certain other DHFR inhibitors, the potential safety and efficacy of PDX for the treatment of PTCL or any other type of cancer; the Company's projected timeline for completing enrollment in the PROPEL trial; and other statements that are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others: that the Company may
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , June 24, 2015 ... ) has announced the addition of the ... Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging ... offering. 2015 New Frontiers in ... Challenges, Emerging Technologies, Competitive Landscape is a ...
(Date:7/1/2015)... WAYNE, Pa. , July 1, 2015 ... services and education, announced today that, as part of ... into an agreement to be acquired by investment firm ... outside private equity investors, Altaris Capital Partners and NewSpring ... founded in 1999, has assisted nearly 5,000 healthcare facilities ...
(Date:7/1/2015)...  goBalto, Inc., the leading provider of cloud-based ... in serving pharmaceutical, biotech and CRO companies. ... trials and restrain costs, but inefficiencies tied to ... these efforts," said Sujay Jadhav , goBalto,s ... encouraged Industry leaders, to embrace cloud-based solutions. Our ...
Breaking Medicine Technology:2015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 3goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2
... NEW YORK, Oct. 11, 2011 PLC Medical Systems, ... RetailInvestorConferences.com presentation is available for on-demand viewing. ... "register/ watch event now" button. PLC Medical ... Investors may download shareholder materials from the "virtual trade ...
... 11, 2011 I-Flow announced today ... purchasing agreement by HealthTrust Purchasing Group, L.P. (HealthTrust), ... covers I-Flow,s flagship ON-Q® products for incisional, nerve ... PainBuster®, ON-Q® SilverSoaker™ Catheters and ON-Q® disposable and ...
Cached Medicine Technology:PLC Medical Systems CEO Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2I-Flow LLC, a Kimberly-Clark Health Care Company Announces Agreement for ON-Q® Products With HealthTrust Purchasing Group 2
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... the global cancer enterprise of Hospital Corporation of America (HCA), as it further ... research, OncLive announced today. , With this new partnership, OncLive’s editorial and ...
(Date:7/1/2015)... ... - (PRWEB) July 01, 2015 , ... Lisa Keys, the widow ... on August 15-16th (MSG Keys’ birthday) in memory of her late husband and all ... and recipient of the Bronze Star Medal, died during a Special Forces training exercise ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... contributing to newly released white paper: “Pro-actively Identifying the High-Cost Patient Population: Insights ... 1st and is available at: http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting ... a top ten list they hope will guide future mesothelioma research. Surviving Mesothelioma ... it now. , More than 450 mesothelioma patients, caregivers, and healthcare ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the ... to lead a national chief executive officer recruitment for Citizens Medical ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
Breaking Medicine News(10 mins):Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3
... a study conducted by Dr. Steriani Elavsky, women passing through ... life// when they exercised. The improvements in heart and respiratory ... perceived quality of life. ,This research was carried ... three groups on a random basis. One group was assigned ...
... that all private hospitals, built on subsidised government land, ... their indoor and outdoor facilities or face contempt of ... the poor "obligatory" at hospitals built on subsidised land, ... H.R. Malhotra said the hospitals are obliged to provide ...
... global tuberculosis (TB) epidemic has levelled off for the first ... 1993. // ,The Global Tuberculosis Control Report released today, ... the percentage of the world's population struck by TB peaked ... ,United Nations Secretary-General Ban Ki-moon described the development as a ...
... system of medicine into English is on the verge of completion. ... in palm leaf manuscripts, would be published soon, according to ... Tamil Nadu. ,As many as six Sidha ... government for two years and produced six volumes, the minister revealed ...
... Woolmer might have been murdered are strengthening.// ... indicates that he might have been strangled in his ... 24 hours after Pakistan’s stunning defeat at the hands of ... Woolmer was found unconscious in his room in Kingston, Jamaica. ...
... of an operation forcing doctors to operated using the lights of ... deliver a caesarean during the incident, which was reported by one ... at a crucial point in a caesarean-section operation on a mother. ... the operating room in Pleiku General Hospital in Gia Lai province, ...
Cached Medicine News:Health News:Private Clinics on Public Land Must Treat Poor Free: Court 2Health News:Global Tuberculosis Epidemic Levelling Off - WHO 2
... non-reactive quality assurance reagent in assays detecting IgG ... and TOXO IgM), IgG and IgM antibodies to ... and IgM antibodies to cytomegalovirus (CMV IgG and ... simplex virus types 1 and 2 (HSV-1 IgG, ...
... VITROS Anti-HCV assay is the third diagnostic,hepatitis ... Drug,Administration capable of being run in a ... with Intellicheck. Now the laboratory staff,can run ... of more than 27 assays, and provide ...
... For use as a non-reactive quality assurance ... immunodeficiency virus type 1 (anti-HIV-1), antibody to ... to human immunodeficiency virus type 1 (HIV-1 ... I (anti-HTLV-I), antibody to hepatitis C virus ...
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
Medicine Products: